The study also indicated that Phylogica Ltd.’s proprietary CPP fusion process significantly improved the efficacy of existing anticancer drugs including the EGFR inhibiting antibody cetuximab (Merck KGAA‘s Erbitux) and the chemotherapy agent docetaxel.
Phylogica Surges On Early CPP Cancer Results
Phylogica is continuing its strong financial year, with the company’s shares surging after it announced that a pilot study for its cell-penetrating peptides (CPPs) showed these were able to kill drug-resistant breast cancer cells in vivo, when linked with the cancer drug Omomyc.
More from Focus On Asia
More from Scrip
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.